Last updated on June 2020

Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.


Brief description of study

The purpose of the protocol, is to describe the use of CabometyxTM (cabozantinib) tablets including the number of dose reductions, dose interruptions and terminations due to (serious) adverse events in subjects with advanced or metastatic renal cell carcinoma (mRCC) treated in real-life clinical setting in 1st line treatment.

Clinical Study Identifier: NCT03647878

Find a site near you

Start Over

Praxis f r H matologie und Internistische Onkologie

Neustadt Am Rübenberge, Germany
9.77miles
  Connect »

Praxis f r H matologie und Internistische Onkologie

Neustadt Am Rübenberge, Germany
9.77miles
  Connect »

Praxis f r H matologie und Internistische Onkologie

Neustadt Am Rübenberge, Germany
9.77miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.